Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)

MLA

Toorop, Alyssa A., et al. “Prospective Trial of Natalizumab Personalised Extended Interval Dosing by Therapeutic Drug Monitoring in Relapsing-Remitting Multiple Sclerosis (NEXT-MS).” Journal of Neurology, Neurosurgery, & Psychiatry (JNNP), vol. 95, no. 5, Jan. 2024, pp. 392–400. EBSCOhost, https://doi.org/10.1136/jnnp-2023-332119.

APA

Toorop, A. A., van Lierop, Z. Y., Gelissen, L. M., Hoitsma, E., Zeinstra, E. M., van Rooij, L. C., van Munster, C. E., Vennegoor, A., Mostert, J. P., Wokke, B. H., Kalkers, N. F., Hoogervorst, E. L., van Eijk, J. J., Roosendaal, C. M., Kragt, J. J., Eurelings, M., van Genugten, J., Nielsen, J., Sinnige, L., … van Kempen, Z. L. (2024). Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS). Journal of Neurology, Neurosurgery, & Psychiatry (JNNP), 95(5), 392–400. https://doi.org/10.1136/jnnp-2023-332119

Chicago

Toorop, Alyssa A, Zoe¨ YGJ van Lierop, Liza MY Gelissen, Elske Hoitsma, Esther MPE Zeinstra, Luuk C van Rooij, Caspar EP van Munster, et al. 2024. “Prospective Trial of Natalizumab Personalised Extended Interval Dosing by Therapeutic Drug Monitoring in Relapsing-Remitting Multiple Sclerosis (NEXT-MS).” Journal of Neurology, Neurosurgery, & Psychiatry (JNNP) 95 (5): 392–400. doi:10.1136/jnnp-2023-332119.